CD177 and neoplasm: Differences in antitumor efficacy of MSC are determined by the dynamics of their interactions with tumor niche components, which in turn are determined by their phenotypic and functional traits (e.g., secretome profile, senescence status, cell surface receptor expression levels), and ultimately depend on the developmental origin of these cells.